The Szent-Györgyi Prize for Progress in Cancer Research was established in honor of NFCR’s co-founder, Albert Szent-Györgyi, M.D., Ph.D., who received the 1937 Nobel Prize for his study of vitamin C and cell respiration. The prize is a symbol of NFCR’s enduring commitment to uphold Dr. Szent-Györgyi’s vision of curing cancer through innovation and collaboration.
The annual prize honors scientists who have made an original discovery or breakthrough in scientific understanding that has had a lasting impact on the cancer field and a direct impact of saving people’s lives. In addition to winning the coveted award itself, prize recipients are given a $25,000 honorarium and attend a gala in their honor. The award serves to highlight the essential role basic research plays in understanding cancer.
2017 Award Recipient
Michael N. Hall, Ph.D.
Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland
The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.
In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.
Monday, May 1 2017
National Press Club
529 14th Street NW
Washington, DC 20045